Senolytics vs Senomorphics: Two Research Approaches to 'Zombie' Cells
Key takeaways
- Senescent cells stop dividing but refuse to die, lingering in tissue and releasing a mix of inflammatory signals called the SASP.
- Senolytics aim to selectively eliminate senescent cells; senomorphics aim to suppress the SASP without removing the cells.
- Much of the evidence comes from cells and animals (PRECLINICAL); a few small human pilot trials exist but are early and disease-focused (HUMAN pilot).
- The pharmaceutical agents named in this research are investigational or prescription drugs studied in trials — not supplements or self-care options.
- These are promising research directions, not proven anti-aging treatments.
Few ideas in longevity science have captured attention like the "zombie cell." The pitch is simple: certain cells in an aging body stop working properly but will not clear out, and getting rid of them might help tissues stay healthier. That idea has split into two distinct research strategies — senolytics and senomorphics. They sound similar and are often mentioned together, but they take opposite approaches. Here is how they differ, what the evidence actually shows, and why caution is still warranted.
What are senescent "zombie" cells?
Cellular senescence is a state in which a cell permanently stops dividing but does not die. In moderation this is useful — it is one way the body limits damaged cells. The problem is that senescent cells accumulate with age and secrete a cocktail of inflammatory molecules known as the senescence-associated secretory phenotype, or SASP. The SASP can disturb neighboring healthy cells and contribute to the low-grade, chronic inflammation often described as "inflammaging." The therapeutic opportunity — and the two strategies below — grew directly out of research into the SASP (Tchkonia et al., Journal of Clinical Investigation, 2013). You can read our primer on what cellular senescence is for more background.
What's the difference between senolytics and senomorphics?
The distinction comes down to remove versus quiet. Senolytics try to kill and clear senescent cells. Senomorphics leave the cells in place but try to silence their harmful secretions. A comprehensive 2025 review lays out both categories and their candidate compounds in detail (review of senolytics and senomorphics, 2025).
| Approach | Goal | Example research compounds | Evidence stage |
|---|---|---|---|
| Senolytics | Selectively eliminate senescent cells | Dasatinib + quercetin, fisetin, navitoclax | Mostly preclinical; small human pilots |
| Senomorphics | Suppress the SASP without killing the cells | Rapamycin, metformin, certain polyphenols | Mostly preclinical |
Senolytics: clearing the cells
The senolytic concept was crystallized in 2015, when researchers used a transcriptomic analysis to identify the survival pathways senescent cells rely on and then paired two compounds — the prescription drug dasatinib with the plant flavonoid quercetin — to disrupt them (Zhu et al., Aging Cell, 2015). This "D+Q" combination has become the reference example. Later work in mice showed that clearing senescent cells could improve physical function and even extend lifespan in old animals (Xu et al., Nature Medicine, 2018) — a striking result, but a PRECLINICAL one.
Senomorphics: quieting the signals
Senomorphics take a gentler-sounding route: rather than eliminating senescent cells, they aim to dial down the SASP so the cells cause less collateral inflammation. Compounds studied in this role include the prescription drugs rapamycin and metformin, along with some dietary polyphenols. Because the cells remain, the theory is that benefits would require ongoing treatment — and nearly all of this evidence remains at the cell and animal stage.
What does the human research show so far?
This is the crucial, sobering part. A few first-in-human pilot studies have tested the D+Q senolytic combination — not in healthy people seeking longevity, but in patients with specific conditions. A small open-label study in idiopathic pulmonary fibrosis reported improvements in some measures of physical function (Justice et al., EBioMedicine, 2019), and a separate pilot in people with diabetic kidney disease showed that senescent-cell markers in tissue actually declined after treatment (Hickson et al., EBioMedicine, 2019). On the flavonoid side, fisetin has been described as a "senotherapeutic" that extended health and lifespan in mice (Yousefzadeh et al., EBioMedicine, 2018), and human trials are ongoing.
Put together: the human data are real but preliminary — tiny samples, specific patient groups, and early endpoints. They are proof of concept, not proof of a general anti-aging benefit.
Are senolytics and senomorphics proven anti-aging treatments?
No. It is important to be clear about this. The animal findings are genuinely exciting, but the human evidence is at the pilot stage and has largely been conducted in the context of disease, under medical supervision, using prescription or investigational drugs. The pharmaceutical agents involved — dasatinib, navitoclax, rapamycin, metformin — are not supplements and carry their own risks and prescribing considerations. "Senolytic" supplements marketed directly to consumers often lean on this early science far more heavily than the evidence justifies. Healthy skepticism is the right posture while larger, controlled human trials are completed.
Where do lifestyle and compounds like Urolithin A fit?
Senescence is only one thread in the larger story of cellular aging. Other threads — mitochondrial quality control, chronic inflammation, metabolic health — are things that everyday habits can influence now: regular exercise, adequate protein, good sleep, and a diet rich in plants and polyphenols.
Standardized Urolithin A belongs to that broader "support the fundamentals" category. It is studied for its support of mitophagy, the recycling of worn-out mitochondria — a different cellular housekeeping process from senescent-cell clearance. To be precise: Urolithin A is not a senolytic, and it is not a treatment for anything. It is a compound some people use to support mitochondrial renewal as part of a healthy-aging routine. If that is your goal, SOMA Urolithin A gummies provide a standardized daily dose. For the senescence side of the picture, see our overview of Urolithin A and cellular senescence.
Support your cellular health, every day
SOMA delivers a high-potency 1,000 mg dose of Urolithin A in one simple daily gummy — no guesswork, no converter-status lottery.
Shop SOMA Urolithin A Gummies →Frequently asked questions
What is the difference between senolytics and senomorphics?
Senolytics aim to selectively kill and clear senescent "zombie" cells, while senomorphics aim to suppress the inflammatory signals (the SASP) those cells release without eliminating them. One removes the cells; the other quiets them.
Are senolytics available to buy?
The best-studied senolytic agents, such as dasatinib, are prescription drugs used only in research or under medical supervision. Some flavonoids studied in this area, like quercetin and fisetin, are sold as supplements, but that does not mean consumer products replicate the doses or results used in studies.
Is Urolithin A a senolytic?
No. Urolithin A is studied for its support of mitophagy — recycling worn-out mitochondria — which is a different process from clearing senescent cells. It is not a senolytic and is not a treatment for any condition.
Do senolytics work in humans?
Early pilot trials in specific patient groups have shown encouraging signals, including a measurable drop in senescent-cell markers in one study. But these trials are small and preliminary, and they do not prove a general anti-aging benefit in healthy people.
Can lifestyle affect senescent cells?
Research suggests regular exercise and overall metabolic health are associated with lower markers of cellular senescence, though this is an active area of study. Everyday habits remain the most evidence-based way to support healthy aging right now.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.